Want to see JP:2929 full AI Analyst Report?
Top Page
Pharma Foods International Co., Ltd.
(2929)
Select Model
Select Model
Rating:60Neutral
Price Target:
¥727.00
▲(17.64% Upside)
Action:Reiterated
Date:09/12/26
The score is held back primarily by weak recent cash generation (negative operating cash flow in 2025–2026 and deeply negative 2026 free cash flow) and still-elevated leverage. These risks are partly offset by supportive valuation (low P/E and ~3.17% dividend yield) and a strong technical uptrend, though momentum indicators are overbought and may limit near-term upside.
Positive Factors
Strong Gross Margin
A gross margin near 80% indicates the company’s products retain substantial value after direct costs, supporting reinvestment in product development, marketing, and customer acquisition. This provides a durable economic foundation even though operating profitability remains modest.
Negative Factors
Sustained Negative Cash Flow
Recent negative operating cash flow and deeply negative free cash flow show that reported earnings are not currently converting into cash. Sustained cash consumption can reduce financial flexibility, increase reliance on funding, and constrain investment or shareholder returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Gross Margin
A gross margin near 80% indicates the company’s products retain substantial value after direct costs, supporting reinvestment in product development, marketing, and customer acquisition. This provides a durable economic foundation even though operating profitability remains modest.
Read all positive factors
Pharma Foods International Co., Ltd. (2929) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥20.80B
Dividend Yield3.06%
Average Volume (3M)258.85K
Price to Earnings (P/E)10.5
Beta (1Y)0.78
Revenue Growth-3.12%
EPS Growth408.74%
CountryJP
Employees613
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)68.32
Shares Outstanding29,079,000
10 Day Avg. Volume393,430
30 Day Avg. Volume258,850
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.23
Price to Sales (P/S)0.26
P/FCF Ratio-3.12
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)54.4
Revenue Forecast (FY)¥69.50B
Pharma Foods International Co., Ltd. Business Overview & Revenue Model
Company Description
Pharma Foods International Co., Ltd. is a Japanese enterprise dedicated to the research, development, and commercialization of ingredients for functional foods. Its diverse product portfolio features items such as Pharma-GABA, Bonepep, Ovopron (a ...
How the Company Makes Money
Pharma Foods International primarily makes money by selling branded health-related consumer products, especially dietary supplements and other functional food/wellness items. Revenue is generated when customers purchase these products through the ...
Pharma Foods International Co., Ltd. Financial Statement Overview
Summary
Income Statement
63
Positive
Balance Sheet
55
Neutral
Cash Flow
28
Negative
| Breakdown | Jul 2026 | Jul 2025 | Jul 2024 | Jul 2023 | Jul 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 63.22B | 65.26B | 62.15B | 68.57B | 60.19B |
| Gross Profit | 50.66B | 52.53B | 48.65B | 55.21B | 48.06B |
| EBITDA | 3.37B | 3.15B | 6.02B | 4.16B | 1.60B |
| Net Income | 1.99B | 368.00M | 3.21B | 3.08B | -374.00M |
Balance Sheet | |||||
| Total Assets | 35.12B | 32.78B | 36.57B | 36.23B | 31.16B |
| Cash, Cash Equivalents and Short-Term Investments | 7.79B | 9.16B | 15.67B | 16.31B | 8.85B |
| Total Debt | 17.17B | 12.66B | 16.90B | 20.12B | 16.89B |
| Total Liabilities | 21.95B | 21.23B | 24.99B | 26.60B | 24.08B |
| Stockholders Equity | 13.17B | 11.55B | 11.59B | 9.63B | 7.07B |
Cash Flow | |||||
| Free Cash Flow | -5.19B | -1.98B | 4.54B | 5.74B | -6.53B |
| Operating Cash Flow | -1.18B | -1.09B | 5.49B | 6.13B | -6.07B |
| Investing Cash Flow | -4.00B | -950.00M | -1.39B | -1.01B | -2.54B |
| Financing Cash Flow | 3.81B | -4.47B | -4.84B | 2.34B | 7.68B |
Pharma Foods International Co., Ltd. Technical Analysis
Positive
618.00
Price Trends
612.39
Positive
601.81
Positive
628.17
Positive
Market Momentum
33.80
Negative
68.16
Neutral
76.68
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2929, the sentiment is Positive. The current price of 618 is below the 20-day moving average (MA) of 653.15, above the 50-day MA of 612.39, and below the 200-day MA of 628.17, indicating a bullish trend. The MACD of 33.80 indicates Negative momentum. The RSI at 68.16 is Neutral, neither overbought nor oversold. The STOCH value of 76.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:2929.
Pharma Foods International Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | ¥9.19B | 11.71 | ― | 2.88% | 0.98% | 69.36% | |
65 Neutral | ¥296.70B | 9.57 | 9.68% | 3.79% | 10.38% | 19.96% | |
60 Neutral | ¥20.80B | 10.51 | ― | 3.06% | -3.12% | 408.74% | |
59 Neutral | ¥10.27B | 30.02 | ― | 1.18% | 25.89% | ― | |
54 Neutral | ¥5.68B | -45.81 | ― | 3.18% | 0.60% | -131.22% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:2929
Pharma Foods International Co., Ltd.
718.00
-89.02
-11.03%
JP:4540
Tsumura & Co
3,878.00
322.17
9.06%
JP:4512
Wakamoto Pharmaceutical Co., Ltd.
296.00
0.49
0.17%
JP:4524
Morishita Jintan Co., Ltd.
2,254.00
90.07
4.16%
JP:4539
Nippon Chemiphar Co., Ltd.
1,573.00
-33.09
-2.06%
Pharma Foods International Co., Ltd. Corporate Events
Pharma Foods Profit Soars Despite Lower Sales, Eyes Further Gains in 2027
Sep 11, 2026
Pharma Foods International reported a 3.1% decline in net sales to ¥63.2 billion for the year ended July 31, 2026, but operating profit rose 11.2% to ¥2.6 billion and profit attributable to owners of parent surged to ¥2.0 billion, l...
Pharma Foods Books Impairment Loss on Onkyo Investment with Limited Consolidated Impact
Sep 9, 2026
Pharma Foods International Co., Ltd. has booked a special loss in its non-consolidated results for the fiscal year ended July 2026, after recognizing an impairment on its equity-method investment in Onkyo Corporation. The company concluded that re...
Pharma Foods Raises Profit Outlook Despite Lower Sales in FY2026
Sep 9, 2026
Pharma Foods International has revised its full-year forecasts for the fiscal year ended July 2026, projecting lower net sales but higher profits than previously expected. Net sales are now seen at JPY 63.2 billion versus a prior JPY 67 billion, w...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.